Franklin Street Advisors Inc. NC Raises Stake in Pfizer Inc. $PFE

Franklin Street Advisors Inc. NC boosted its position in Pfizer Inc. (NYSE:PFE) by 27.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,831 shares of the biopharmaceutical company’s stock after buying an additional 11,668 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Pfizer were worth $1,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter worth approximately $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the first quarter valued at approximately $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the first quarter valued at approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $27.37 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $155.59 billion, a PE ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. The business has a 50 day moving average of $24.67 and a 200 day moving average of $24.15. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.